Early results were positive in a study of the preventive treatment of COVID-19 with xagevimab/cilgavimab for patients who were unlikely to respond sufficiently or at all to vaccination.
COVID-19 Vaccines in Patients with Immune-Mediated Inflammatory Diseases
A member of the ACR COVID-19 Vaccine Clinical Guidance Task Force provides an update on the latest data.
Checkpoint Inhibitor Therapy for Patients with Immune-Mediated Inflammatory Diseases (Video)
Checkpoint inhibitor therapy for cancer holds great potential for durable response rates, but immune-related adverse events may be its Achilles’ heel.
Preventing and Managing Serious Infection in Biologically Treated Patients
Hepatitis C infection has presented a profound challenge to physicians— including rheumatologists, dermatologists and gastroenterologists — caring for patients with immune-mediated inflammatory diseases.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Deadly but Preventable: HBV Reactivation After Immunosuppressive Treatment
Individuals with clinically unapparent HBV and concomitant immune-mediated inflammatory diseases (IMIDs) (e.g., rheumatoid arthritis, psoriasis, inflammatory bowel disease and others) are particularly vulnerable to HBV reactivation when immunosuppressed.